This report sustained the role of CTLA-4 as a regulator of T-cell activation and immune tolerance and highlighted that CTLA-4 pathway alteration can lead to inflammatory demyelination, thus having significant implications for the development of new possible treatments for autoimmune disorders such as MS [154]. Here, CTLA4 is linked to autoimmune disease.